In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2
Page 1 of 1
In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2
Jon Moulton Wed Nov 28, 2012 3:00 pm
Castellanos EC, Rosas I, Solanes A, Bielsa I, Lazaro C, Carrato C, Hostalot C, Prades P, Roca-Ribas F, Blanco I, Serra E. In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. Eur J Hum Genet. 2012;[Epub ahead of print] doi:10.1038/ejhg.2012.261
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA -
Similar topics» Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>G) abrogated in vitro using an antisense morpholino oligonucleotide
» Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO)
» Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation
» Whole USH2A Gene Sequencing Identifies Several New Deep Intronic Mutations
» Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency
» Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO)
» Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation
» Whole USH2A Gene Sequencing Identifies Several New Deep Intronic Mutations
» Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum